Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 21,700 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total value of $524,706.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $21,480.00.

Enliven Therapeutics Trading Down 10.0 %

ELVN stock traded down $2.41 during midday trading on Friday, hitting $21.74. 323,088 shares of the company's stock were exchanged, compared to its average volume of 204,598. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The stock has a market capitalization of $1.06 billion, a PE ratio of -11.44 and a beta of 1.04. The business has a 50-day simple moving average of $24.66 and a two-hundred day simple moving average of $24.39.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Barclays PLC boosted its position in Enliven Therapeutics by 295.8% in the 3rd quarter. Barclays PLC now owns 56,217 shares of the company's stock valued at $1,435,000 after buying an additional 42,012 shares during the period. First Turn Management LLC raised its position in Enliven Therapeutics by 29.5% in the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company's stock valued at $13,666,000 after purchasing an additional 121,849 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Enliven Therapeutics by 9.9% in the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock valued at $19,164,000 after buying an additional 67,813 shares during the period. Ally Bridge Group NY LLC acquired a new position in shares of Enliven Therapeutics during the third quarter worth about $5,998,000. Finally, Patient Square Capital LP acquired a new position in shares of Enliven Therapeutics during the third quarter worth about $2,313,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Analysts Set New Price Targets

ELVN has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. BTIG Research began coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a "buy" rating and a $42.00 price target for the company. Finally, Robert W. Baird lifted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of "Buy" and an average target price of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.